NICE (UK) recommends Exkivity to treat (EGFR) exon 20 insertion gene mutation-positive advanced non-small-cell lung cancer
The UK National Institute for Health and Care Excellence (NICE) has issued final guidance recommending using Takeda’s mobocertinib (Exkivity) to treat advanced lung cancer
Mobocertinib has been recommended to treat epidermal growth factor receptor (EGFR) exon 20 insertion gene mutation-positive advanced non-small-cell lung cancer (NSCLC) patients who have previously received platinum-based chemotherapy. The new targeted therapy will be given as four capsules a day at home.
NICE medicines evaluation interim director Helen Knight said: “This is the first treatment approved by NICE that targets this specific gene mutation in people with advanced non-small-cell lung cancer. “The evidence shows it not only extends people’s lives but also extends how long people have before their cancer gets worse.”
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.